Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease

Open access
Lin, Ai-Ling, Zheng, Wei, Halloran, Jonathan J, Burbank, Raquel R, Hussong, Stacy A, Hart, Matthew J, Javors, Martin, Shih, Yen-Yu Ian, Muir, Eric, Fonseca, Rene Solano, Strong, Randy, Richardson, Arlan G, Lechleiter, James D, Fox, Peter T, Galvan, Veronica·2013·Journal of Cerebral Blood Flow & Metabolism

Abstract

Vascular pathology is a major feature of Alzheimer’s disease (AD) and other dementias. We recently showed that chronic administration of the target-of-rapamycin (TOR) inhibitor rapamycin, which extends lifespan and delays aging, halts the progression of AD-like disease in transgenic human (h)APP mice modeling AD when administered before disease onset. Here we demonstrate that chronic reduction of TOR activity by rapamycin treatment started after disease onset restored cerebral blood flow (CBF) and brain vascular density, reduced cerebral amyloid angiopathy and microhemorrhages, decreased amyloid burden, and improved cognitive function in symptomatic hAPP (AD) mice. Like acetylcholine (ACh), a potent vasodilator, acute rapamycin treatment induced the phosphorylation of endothelial nitric oxide (NO) synthase (eNOS) and NO release in brain endothelium. Administration of the NOS inhibitor L-NG-Nitroarginine methyl ester reversed vasodilation as well as the protective effects of rapamycin on CBF and vasculature integrity, indicating that rapamycin preserves vascular density and CBF in AD mouse brains through NOS activation. Taken together, our data suggest that chronic reduction of TOR activity by rapamycin blocked the progression of AD-like cognitive and histopathological deficits by preserving brain vascular integrity and function. Drugs that inhibit the TOR pathway may have promise as a therapy for AD and possibly for vascular dementias.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/jcbfm.2013.82

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 208

Metadata

Authors
Lin, A.-L., Zheng, W., Halloran, J. J., Burbank, R. R., Hussong, S. A., Hart, M. J., Javors, M., Shih, Y.-Y. I., Muir, E., Fonseca, R. S., Strong, R., Richardson, A. G., Lechleiter, J. D., Fox, P. T., & Galvan, V.
Venue
Journal of Cerebral Blood Flow & Metabolism
Published
2013-06-26
Volume
33
Issue
9
Pages
1412-1421
ISSN
  • 0271-678X (ISSN-L)
  • 1559-7016
OpenAlex
W2059278059
Cited by
208
References
20
FWCI
9.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease. https://app.cochat.ai/papers/10.1038/jcbfm.2013.82
The paper
Lin, A.-L., Zheng, W., Halloran, J. J., Burbank, R. R., Hussong, S. A., Hart, M. J., Javors, M., Shih, Y.-Y. I., Muir, E., Fonseca, R. S., Strong, R., Richardson, A. G., Lechleiter, J. D., Fox, P. T., & Galvan, V. (2013). Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1038/jcbfm.2013.82

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.